Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1NET 1Gastrointestinal 1Endocrine 1

Conditions

Multiple Myeloma 2Neuroendocrine Tumors 1Neoplasms 1Lymphoma 1Gastrointestinal Neoplasms 1

Interventions

Dexamethasone 33Lenalidomide 14pomalidomide 12daratumumab 12Bortezomib 12venetoclax 7Cyclophosphamide 7isatuximab 6Therapeutics 6trametinib 4carfilzomib 4Trimethoprim, Sulfamethoxazole Drug Combination 4gamma-Globulins 3fludarabine 3dabrafenib 3Vemurafenib 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Drug Therapy 3Denosumab 3Ciprofloxacin 3Calcium Dobesilate 3ridaforolimus 2pembrolizumab 2molibresib 2liposomal amphotericin B 2fludarabine phosphate 2cobimetinib 2afuresertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Referral and Consultation × Plasma cell × Clear all
NCT06908629 2025-08-26

Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors

Barbara Ann Karmanos Cancer Institute

Phase NA Recruiting
120 enrolled
EndocrineGastrointestinalNETPlasma cell

Gastrointestinal Neoplasms, Multiple Myeloma, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡